Journal
EXPERIMENTAL AND THERAPEUTIC MEDICINE
Volume 22, Issue 1, Pages -Publisher
SPANDIDOS PUBL LTD
DOI: 10.3892/etm.2021.10191
Keywords
portal vein thrombosis; Budd-Chiari; cirrhosis; portal cavernoma; anticoagulation; LMWH
Categories
Ask authors/readers for more resources
Portal vein thrombosis (PVT) is a common complication in cirrhotic patients, but can also occur as a primary vascular condition. The pathogenesis of PVT is complex and involves multiple factors, with the JAK2 mutation accepted as a contributing factor.
Portal vein thrombosis (PVT) is a frequent complication in cirrhotic patients, but it may also exist as a basic vascular condition even without any liver damage. Local and systemic factors play a significant role in the pathogenesis of PVT; yet, in practice, more than one factor may be identified. PVT can be considered a result of liver fibrosis and hepatic insufficiency. The JAK2 mutation has been accepted as a factor producing PVT. In general, the anticoagulants are recommended but this therapy should be used carefully in treating patients that associate coagulopathy or thrombocytopenia and esophageal varices. Acute PVT without bowel infarction has a good prognosis. In liver cirrhosis, the mortality due to hemorrhage is higher than in chronic PVT. Therefore, for the patients with PVT, the survival rate is decreased by 55% in two years, due to hepatic insufficiency. Regarding the treatment, LMWH (low molecular weight heparine) is the most utilized in patients with cirrhosis, non-malignancies, infections, or those who are awaiting a liver transplant. DOACs (direct-acting oral anticoagulants) may be used in the rest of the medical conditions, being safe and equal to LMWH.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available